The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B

Abstract Background Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. Objectives To evaluate if patient‐reported outcome measures (PROMs) improved in Canadian persons with hemophilia who switched from standar...

Full description

Bibliographic Details
Main Authors: Haowei (Linda) Sun, Ming Yang, Man‐Chiu Poon, Adrienne Lee, K. Sue Robinson, Michelle Sholzberg, John Wu, Alfonso Iorio, Victor Blanchette, Manuel Carcao, Robert J. Klaassen, Shannon Jackson
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
extended half‐life
hemophilia A
hemophilia B
patient‐reported outcomes
quality of life
Online Access:https://doi.org/10.1002/rth2.12601

Internet

https://doi.org/10.1002/rth2.12601

Similar Items